Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - A Recap On The Pharmaceuticals & Healthcare Outlook For 2017: Latin America - SEPT 2017

Americas July 2017 / Latin America / Industry

The Latin American pharmaceutical and healthcare market is set for expansion in 2017 but prolonged macroeconomic headwinds pose downside risks. The Latin American market will be impacted by the failure to pass the Trans-Pacific Partnership, as presently constituted, putting on hold the debate over patent protection and lessening the pressure on the region's health systems. The short-term picture is challenging but the region's long-standing liberalisation efforts and strong consumer base mean that Latin American pharmaceutical markets remain an investment opportunity for pharmaceutical companies. Ongoing trends, such as the roll-out of universal healthcare, are expected to continue and will shape opportunities for the region.


Industry Trend Analysis - Value-Based Medicine Pricing System To Challenge Drugmakers - SEPT 2017

Asia July 2017 / Japan / Industry

Reforms to drive higher efficiency in Japan's pharmaceutical sector will continue as the country seeks to curb costs, while adapting to its ageing demographic profile. Regulatory reforms on outcomes based healthcare announced in 2017 by the Ministry of Health, Labor and Welfare, are centred on improving the experience of care, improving the health of populations, whilst simultaneously reducing per capita costs of healthcare. Pharmaceutical companies will need to embrace the value-based care trend and increase the attractiveness of their medicines to the healthcare system.


Industry Trend Analysis - Reagila Is A New Option In A Crowded Market - SEPT 2017

Emerging Europe July 2017 / Europe / Industry

As an atypical antipsychotic, Reagila joins a crowded market and sales growth will be slow but steady, mirroring the experience with Vraylar in the US. This is an effective drug with potential in other conditions and its development for the treatment of predominant negative symptoms of schizophrenia targets a serious unmet need.


Industry Trend Analysis - A Recap On The Pharmaceuticals & Healthcare Outlook For 2017: Middle East & North Africa - SEPT 2017

Middle East & Africa July 2017 / Middle East / Industry

The MENA region's pharmaceutical and healthcare markets will be shaped by a range of opportunities and challenges in 2017. Ongoing trends, such as the rollout of compulsory health insurance schemes, generic substitution and medical tourism are expected to continue shaping the pharmaceutical market. Challenges will intensify, however, and while discrepancies exist at the country level, growth is expected to be muted in 2017 as the impact of a slow recovery within the oil sector will continue to impact pharmaceutical spending.


Industry Trend Analysis - Pharmacy Revenues To Continue To Come Under Pressure - SEPT 2017

Western Europe July 2017 / United Kingdom / Industry

Community pharmacies in England will continue to face revenue challenges as the government continues to seek cost savings in the face of the rising demand for pharmaceuticals. As dispensing becomes a commodity, consumer demands rise and as alternative selling channels emerge, pharmacies will need to alter their business models to maintain sustainable revenue streams. While multiple pharmacy contractors will be placed better to achieve this via economies of scale, the flexibility of independent pharmacies or smaller chains can be utilised to tailor services to meet personal consumer needs.